Fusen Pharmaceutical Company Limited (1652.HK) HKSE
Currency In HKD
- General
- Statistics
- Historical Data
- Profile
- Financials
Currency In HKD
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
1131
First IPO Date
July 11, 2018
| Name | Title | Pay | Year Born |
| Zhiming Cao | Chief Executive Officer & Executive Chairman | 1.95M | 1986 |
| Taisheng Hou | Executive Director | 94,917 | 1963 |
| Yongsheng Chi | Executive Director | 94,917 | 1962 |
| Qingfen Meng | Executive Director | 94,917 | 1965 |
| Yuk Hong Yeung | Company Secretary | 0 | 1991 |
| Zhen Li | Chief Financial Officer | 0 | 1978 |
Fusen Pharmaceutical Company Limited operates as an investment holding enterprise, primarily engaged in the manufacturing and distribution of a diverse range of pharmaceutical products across the People's Republic of China. Its extensive product portfolio includes specific cold remedies based on Shuanghuanglian, offered as both oral solutions and injections, alongside medications like flunarizine hydrochloride capsules and compound ferrous sulfate granules. The company further provides Yuanhu Zhitong oral solutions, Ganweikang tablets, and Yixinkang tablets. Beyond these, Fusen actively researches, develops, produces, and markets a variety of proprietary Chinese medicines and modern Western pharmaceuticals, targeting conditions such as colds, fevers, cardiovascular ailments, and anemia. Additionally, the firm offers business management and advisory services. Fusen Pharmaceutical Company Limited was established in 2003 and is headquartered in Nanyang, China.